Oxalamide-Functionalized Metal Organic Frameworks for CO2 Adsorption

Metal-organic frameworks (MOFs) have received great attention in recent years as potential adsorbents for CO2 capture due to their unique properties. However, the high cost and their tedious synthesis procedures impede their industrial application. A series of new CO2-philic oxalamide-functionalized MOFs have been solvothermally synthesized: {[Zn-3(mu(8)-OATA)(1.5)(H2O)(2)(DMF)]center dot 5/2H(2)O center dot 5DMF}(n) (Zn-OATA), {[NH2(CH3)(2)][Cd(mu(4)-HOATA)]center dot H2O center dot DMF}(n) (Cd-OATA), and {[Co-2(mu(7)-OATA)(H2O)(DMF)(2)]center dot 2H(2)O center dot 3DMF}(n) (Co-OATA) (H(4)OATA = N,N'-bis(3,5-dicarboxyphenyl)oxalamide). In Zn-OATA, the [Zn-2(CO2)(4)] SBUs are connected by OATA(4-) ligands into a 3D framework with 4-connected NbO topology. In Cd-OATA, two anionic frameworks with a dia topology interpenetrated each other to form a porous structure. In Co-OATA, [Co-2(CO2)(4)] units are linked by four OATA(4-) to form a 3D framework with binodal 4,4-connected 4(2)center dot 8(4) PtS-type topology. Very interestingly, Cu-OATA can be prepared from Zn-OATA by a facile metal ions exchange procedure without damaging the structure while the CO2 adsorption ability can be largely enhanced when Zn(II) metal ions are exchanged to Cu(II). These new MOFs possess channels decorated by the CO2-philic oxalamide groups and accessible open metal sites, suitable for highly selective CO2 adsorption. Cu-OATA exhibits a significant CO2 adsorption capacity of 25.35 wt % (138.85 cm(3)/g) at 273 K and 9.84 wt % (50.08 cm(3)/g) at 298 K under 1 bar with isosteric heat of adsorption (Qst) of about 25 kJ/mol. Cu-OATA presents a very high selectivity of 5.5 for CO2/CH4 and 43.8 for CO2/N-2 separation at 0.1 bar, 298 K. Cd-OATA exhibits a CO2 sorption isotherm with hysteresis that can be originated from structural rearrangements. Cd-OATA adsorbs CO2 up to 11.90 wt % (60.58 cm(3)/g) at 273 K and 2.26 wt % (11.40 cm(3)/g) at 298 K under 1 bar. Moreover, these new MOFs exhibit high stability in various organic solvents, water, and acidic or basic media. The present work opens a new opportunity in the development of improved and cost-effective MOF adsorbents for highly efficient CO2 capture.YScientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [215Z252]; Changjiang Scholars and Innovative Research Team in University of the Chinese Ministry of EducationProgram for Changjiang Scholars & Innovative Research Team in University (PCSIRT) [IRT_15R52]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [NSFC-U1663225]; Ministry of Science and Technology [B20002]; Ministry of Education of ChinaMinistry of Education, China; project DepollutAir of the EU program Interreg V France-Wallonie-VlaanderenThis work has been supported by The Scientific and Technological Research Council of Turkey (TUBITAK) (Project No. 215Z252). The authors would like to acknowledge Dr. Tug.ce Gunay Semerci for her helpful discussions and comments. This work is also financially supported by Changjiang Scholars and Innovative Research Team in University (IRT_15R52) of the Chinese Ministry of Education, the National Natural Science Foundation of China (NSFC-U1663225), Program of Introducing Talents of Discipline to Universities-Plan 111 (Grant No. B20002) from the Ministry of Science and Technology and the Ministry of Education of China, and the project DepollutAir of the EU program Interreg V France-Wallonie-Vlaanderen.WOS:000677540900055PubMed: 3425118

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess the optimal dosing regimen in a real-life setting. We retrospectively analyzed 263 patients with mCRC from multiple medical oncology clinics in Turkey. Treatment responses and prognostic factors for survival were evaluated using univariate and multivariate analysis. Of the patients, 120 were male and 143 were female; 28.9% of tumors were located in the rectum. RAS mutations were present in 3.0% of tumors, while BRAF, K-RAS, and N-RAS mutations were found in 3.0%, 29.7%, and 25.9% of tumor tissues, respectively. Dose escalation was preferred in 105 (39.9%) patients. The median treatment duration was 3.0 months, with an objective response rate (ORR) of 4.9%. Grade ≥ 3 treatment-related toxicity occurred in 133 patients, leading to discontinuation, interruption, and modification rates of 50.6%, 43.7%, and 79.0%, respectively. Median progression-free survival (PFS) and overall survival (OS) were 3.0 and 8.1 months, respectively. RAS/RAF mutation (hazard ratio [HR] 1.5, 95% confidence interval [CI] 1.1–2.3; P = 0.01), pre-treatment carcinoembryonic antigen (CEA) levels (HR 1.6, 95% CI 1.1–2.3; P = 0.008), and toxicity-related treatment interruption or dose adjustment (HR 1.6, 95% CI 1.1–2.4; P = 0.01) were identified as independent prognostic factors for PFS. Dose escalation had no significant effect on PFS but was associated with improved OS (P < 0.001). Independent prognostic factors for OS were the initial TNM stage (HR 1.3, 95% CI 1.0–1.9; P = 0.04) and dose interruption/adjustment (HR 0.4, 95% CI 0.2–0.9; P = 0.03). Our findings demonstrate the efficacy and safety of regorafenib. Treatment line influences the response, with dose escalation being more favorable than adjustment or interruption, thus impacting survival

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.

IntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.IntroductionMale breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients.We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer.MethodsThis study is a multicenter, retrospective study. We included male patients with HR + and HER2-metastatic breast cancer who received palbociclib or ribociclib as first-line treatment. Our primary endpoints were progression-free survival (PFS), overall response rates (ORR), and drug-related adverse effects.ResultsA total of 46 male patients from 27 institutions were enrolled. The median age at initiation of CDK 4/6 inhibitors was 63.64 +/- 13.69 years, with a median follow-up of 21.33 (95% CI 14.92-27.74) months. The ORR were 84% for palbociclib and 76.2% for ribociclib. The mPFS for the entire cohort was 28.06 months (95% CI 18.70-37.42). No significant difference in PFS was observed between palbociclib and ribociclib (mPFS: 24.46 months (95% CI 11.51-37.42) vs 28.33 months (95% CI 14.77-41.88), respectively, p = 0.211). No new adverse events were reported.DiscussionThis study demonstrates that palbociclib and ribociclib are effective and safe options for first-line treatment in male patients with HR + /HER2 - metastatic breast cancer. However, further prospective studies are warranted to establish their efficacy in this population